Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

Antimicrobial Proteins

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reviewing the Implication of Aldehyde Dehydrogenases in Male Reproduction: Prospects for New Therapeutic Approaches.

Pharmaceuticals (Basel, Switzerland)·2026

Same author

Exploring the Role and Pathophysiological Significance of Aldehyde Dehydrogenase 1B1 (ALDH1B1) in Human Lung Adenocarcinoma.

International journal of molecular sciences·2024

Same author

Analysis of Human Milk Microbiota in Northern Greece by Comparative 16S rRNA Sequencing vs. Local Dairy Animals.

Nutrients·2024

Same author

Expression and purification of human interferon alpha 2a (IFNα2a) in the methylotrophic yeast Pichia pastoris.

Protein expression and purification·2023

Same author

Investigating the Functional Roles of Aldehyde Dehydrogenase 3A1 in Human Corneal Epithelial Cells.

International journal of molecular sciences·2023

Same author

The Concept of Cancer Stem Cells: Elaborating on ALDH1B1 as an Emerging Marker of Cancer Progression.

Life (Basel, Switzerland)·2023

Search research articles

Related Experiment Video

Updated: Sep 18, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Interferon Lambda: The Next Frontier in Antiviral Therapy?

Sofia Chronopoulou¹, Ilias Tsochantaridis¹

¹Department of Molecular Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.

Pharmaceuticals (Basel, Switzerland)

|June 27, 2025

Summary

Type III interferons (IFN-λ) offer targeted antiviral therapy with fewer side effects due to their specific receptor binding on epithelial cells. Clinical trials show promise for IFN-λ in treating viral infections like COVID-19 and hepatitis.

Keywords:

COVID-19 antiviral therapy cytokines hepatitis B hepatitis C hepatitis D interferon lambda

More Related Videos

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Experiment Videos

Last Updated: Sep 18, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Area of Science:

Immunology
Virology
Biotechnology

Background:

Type III interferons (IFN-λ) are a distinct class of interferons with unique signaling pathways.
Unlike Type I interferons, IFN-λ primarily targets epithelial cells via a specific receptor complex.
This targeted action suggests a reduced side-effect profile for therapeutic applications.

Purpose of the Study:

To review the molecular characteristics, signaling, and innate immune roles of IFN-λ in epithelial tissues.
To critically evaluate the antiviral efficacy of IFN-λ in clinical trials for COVID-19 and hepatitis B, C, and D.
To explore the potential of engineered recombinant IFN-λ as a therapeutic agent with an improved safety profile.

Main Methods:

Literature review of molecular structure, signaling pathways, and innate immunity.
Systematic analysis of published clinical trial data for IFN-λ in viral infections.
Discussion of recombinant protein engineering and advanced drug delivery systems for IFN-λ.

Main Results:

IFN-λ exhibits specific receptor binding on epithelial cells, differentiating it from Type I interferons.
Clinical trials indicate potential efficacy of IFN-λ against SARS-CoV-2, HBV, HCV, and HDV.
Engineered recombinant IFN-λ demonstrates a favorable side-effect profile compared to Type I interferons.

Conclusions:

IFN-λ represents a promising therapeutic candidate for viral infections due to its targeted action and reduced toxicity.
Further development of recombinant IFN-λ using advanced expression and delivery systems is warranted.
IFN-λ holds significant potential for treating epithelial-centric viral diseases.